# Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

> **NCT00081861** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Avastin
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00081861
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2012-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081861, "Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00081861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*